These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 10918072)
1. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. Smith AJ; van Helvoort A; van Meer G; Szabo K; Welker E; Szakacs G; Varadi A; Sarkadi B; Borst P J Biol Chem; 2000 Aug; 275(31):23530-9. PubMed ID: 10918072 [TBL] [Abstract][Full Text] [Related]
2. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. van Helvoort A; Smith AJ; Sprong H; Fritzsche I; Schinkel AH; Borst P; van Meer G Cell; 1996 Nov; 87(3):507-17. PubMed ID: 8898203 [TBL] [Abstract][Full Text] [Related]
3. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein. Abulrob AG; Gumbleton M Biochem Biophys Res Commun; 1999 Aug; 262(1):121-6. PubMed ID: 10448079 [TBL] [Abstract][Full Text] [Related]
4. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. Horio M; Chin KV; Currier SJ; Goldenberg S; Williams C; Pastan I; Gottesman MM; Handler J J Biol Chem; 1989 Sep; 264(25):14880-4. PubMed ID: 2570070 [TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Kakumoto M; Sakaeda T; Takara K; Nakamura T; Kita T; Yagami T; Kobayashi H; Okamura N; Okumura K Cancer Sci; 2003 Jan; 94(1):81-6. PubMed ID: 12708479 [TBL] [Abstract][Full Text] [Related]
6. Differential Coupling of Binding, ATP Hydrolysis, and Transport of Fluorescent Probes with P-Glycoprotein in Lipid Nanodiscs. Li MJ; Nath A; Atkins WM Biochemistry; 2017 May; 56(19):2506-2517. PubMed ID: 28441502 [TBL] [Abstract][Full Text] [Related]
7. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein. Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401 [TBL] [Abstract][Full Text] [Related]
8. ATPase activity of nucleotide binding domains of human MDR3 in the context of MDR1. Ishigami M; Tominaga Y; Nagao K; Kimura Y; Matsuo M; Kioka N; Ueda K Biochim Biophys Acta; 2013 Apr; 1831(4):683-90. PubMed ID: 23305784 [TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700 [TBL] [Abstract][Full Text] [Related]
10. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Takara K; Sakaeda T; Kakumoto M; Tanigawara Y; Kobayashi H; Okumura K; Ohnishi N; Yokoyama T Oncol Res; 2009; 17(11-12):527-33. PubMed ID: 19806783 [TBL] [Abstract][Full Text] [Related]
11. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495 [TBL] [Abstract][Full Text] [Related]
12. ABC transporters in lipid transport. Borst P; Zelcer N; van Helvoort A Biochim Biophys Acta; 2000 Jun; 1486(1):128-44. PubMed ID: 10856718 [TBL] [Abstract][Full Text] [Related]
13. Domain exchangeability between the multidrug transporter (MDR1) and phosphatidylcholine flippase (MDR2). Zhou Y; Gottesman MM; Pastan I Mol Pharmacol; 1999 Nov; 56(5):997-1004. PubMed ID: 10531406 [TBL] [Abstract][Full Text] [Related]
14. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. Urbatsch IL; Beaudet L; Carrier I; Gros P Biochemistry; 1998 Mar; 37(13):4592-602. PubMed ID: 9521779 [TBL] [Abstract][Full Text] [Related]
15. Xenobiotic transport differences in mouse mesangial cell clones expressing mdr1 and mdr3. Ernest S; Bello-Reuss E Am J Physiol; 1996 Mar; 270(3 Pt 1):C910-9. PubMed ID: 8638674 [TBL] [Abstract][Full Text] [Related]
16. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Taub ME; Podila L; Ely D; Almeida I Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365 [TBL] [Abstract][Full Text] [Related]
18. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437 [TBL] [Abstract][Full Text] [Related]
19. Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippase. Zhou Y; Gottesman MM; Pastan I Mol Cell Biol; 1999 Feb; 19(2):1450-9. PubMed ID: 9891078 [TBL] [Abstract][Full Text] [Related]
20. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]